Prevention and Potential Treatment Strategies for Respiratory Syncytial Virus

被引：9

作者：

Sun, Bo-Wen ^{[1
,2
]}

Zhang, Peng-Peng ^{[1
,2
]}

Wang, Zong-Hao ^{[1
,2
]}

Yao, Xia ^{[1
,2
]}

He, Meng-Lan ^{[1
,2
]}

Bai, Rui-Ting ^{[1
,2
]}

Che, Hao ^{[1
,2
]}

Lin, Jing ^{[3
]}

Xie, Tian ^{[1
,2
]}

Hui, Zi ^{[1
,2
]}

Ye, Xiang-Yang ^{[1
,2
]}

Wang, Li-Wei ^{[1
,2
]}

机构：

[1] Hangzhou Normal Univ, Sch Pharm, Hangzhou 311121, Peoples R China

[2] Hangzhou Normal Univ, Collaborat Innovat Ctr Tradit Chinese Med Zhejian, Engn Lab Dev & Applicat Tradit Chinese Med, Key Lab Elemene Class Anticanc Chinese Med, Hangzhou 311121, Peoples R China

[3] Hangzhou Haolu Pharma Co, Drug Discovery, Hangzhou 311121, Peoples R China

来源：

MOLECULES | 2024年 / 29卷 / 03期

关键词：

respiratory syncytial virus (RSV); monoclonal antibodies; vaccine; molecule inhibitor; HISTONE DEACETYLASE INHIBITORS; MATRIX PROTEIN; NONSTRUCTURAL PROTEINS; NLRP3; INFLAMMASOME; FUSION INHIBITOR; NUCLEAR EXPORT; YOUNG-CHILDREN; MESSENGER-RNA; N-TERMINUS; P-PROTEIN;

D O I：

10.3390/molecules29030598

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Respiratory syncytial virus (RSV) is a significant viral pathogen that causes respiratory infections in infants, the elderly, and immunocompromised individuals. RSV-related illnesses impose a substantial economic burden worldwide annually. The molecular structure, function, and in vivo interaction mechanisms of RSV have received more comprehensive attention in recent times, and significant progress has been made in developing inhibitors targeting various stages of the RSV replication cycle. These include fusion inhibitors, RSV polymerase inhibitors, and nucleoprotein inhibitors, as well as FDA-approved RSV prophylactic drugs palivizumab and nirsevimab. The research community is hopeful that these developments might provide easier access to knowledge and might spark new ideas for research programs.

引用

页数：18

共 50 条

[41] Respiratory Syncytial Virus Infection: An Update
Soni, Akshita
Kabra, S. K.
Lodha, Rakesh
INDIAN JOURNAL OF PEDIATRICS, 2023, 90 (12) : 1245 - 1253
[42] Prevention of serious respiratory syncytial virus-related illness. II: Immunoprophylaxis
Groothuis, Jessie R.
Hoopes, J. Michael
Hemming, Val G.
ADVANCES IN THERAPY, 2011, 28 (02) : 110 - 125
[43] Prevention of respiratory syncytial virus from 1991 to 2024: a systematic review and bibliometrics analysis
Li, Xue
Yu, Xia
Du, Zixi
Zhang, Ling
Wang, Yeyuan
Wu, Ying
Lin, Yonghong
He, Yulei
TRANSLATIONAL PEDIATRICS, 2024, 13 (10) : 1858 - 1869
[44] New options in the treatment of respiratory syncytial virus disease
Mejias, Asuncion
Ramilo, Octavio
JOURNAL OF INFECTION, 2015, 71 : S80 - S87
[45] Respiratory Syncytial Virus
Nam, Hannah H.
Ison, Michael G.
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE, 2021, 42 (06) : 788 - 799
[46] Treatment of respiratory syncytial virus with palivizumab: a systematic review
Hu, Jia
Robinson, Joan L.
WORLD JOURNAL OF PEDIATRICS, 2010, 6 (04) : 296 - 300
[47] Overview of prevention and management of acute bronchiolitis due to respiratory syncytial virus
Ghazaly, Marwa
Nadel, Simon
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2018, 16 (12) : 913 - 928
[48] The Use of Humanized Monoclonal Antibodies for the Prevention of Respiratory Syncytial Virus Infection
Lanari, Marcello
Vandini, Silvia
Arcuri, Santo
Galletti, Silvia
Faldella, Giacomo
CLINICAL & DEVELOPMENTAL IMMUNOLOGY, 2013,
[49] Cost-effectiveness of bivalent respiratory syncytial virus prefusion F vaccine for prevention of respiratory syncytial virus among older adults in Germany
Averin, Ahuva
Huebbe, Bennet
Atwood, Mark
Bayer, Lea J.
Lade, Caroline
von Eiff, Christof
Sato, Reiko
EXPERT REVIEW OF VACCINES, 2025, 24 (01) : 1 - 10
[50] Respiratory syncytial virus pulmonary infections in adults - disease burden and prevention
Waterer, Grant W.
Metersky, Mark
CURRENT OPINION IN PULMONARY MEDICINE, 2025, 31 (03) : 223 - 229

← 1 2 3 4 5 →